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IL-10-produced by human 
transitional B-cells down-regulates 
CD86 expression on B-cells 
leading to inhibition of CD4+T-cell 
responses
Estefania  Nova-Lamperti1, Giorgia Fanelli1, Pablo D. Becker1, Prabhjoat Chana2, 
Raul Elgueta1, Philippa C. Dodd1, Graham M. Lord1,3, Giovanna Lombardi1,* & 
Maria P. Hernandez-Fuentes1,3,*
A novel subset of human regulatory B-cells has recently been described. They arise from within the 
transitional B-cell subpopulation and are characterised by the production of IL-10. They appear to be 
of significant importance in regulating T-cell immunity in vivo. Despite this important function, the 
molecular mechanisms by which they control T-cell activation are incompletely defined. Here we show 
that transitional B-cells produced more IL-10 and expressed higher levels of IL-10 receptor after CD40 
engagement compared to other B-cell subsets. Furthermore, under this stimulatory condition, CD86 
expressed by transitional B-cells was down regulated and T-cell proliferation was reduced. We provide 
evidence to demonstrate that the down-regulation of CD86 expression by transitional B-cells was due to 
the autocrine effect of IL-10, which in turn leads to decreased T-cell proliferation and TNF-α production. 
This analysis was further extended to peripheral B-cells in kidney transplant recipients. We observed 
that B-cells from patients tolerant to the graft maintained higher IL-10 production after CD40 ligation, 
which correlates with lower CD86 expression compared to patients with chronic rejection. Hence, the 
results obtained in this study shed light on a new alternative mechanism by which transitional B-cells 
inhibit T-cell proliferation and cytokine production.
B-lymphocytes have traditionally been associated with antibody production and antigen presentation. However, 
a new regulatory role has been ascribed to B-cells in mice1–9 and humans10–12. In mice, IL-10 production has 
been proposed as the main regulatory mechanism used by B-cells in experimental autoimmune encephalomy-
elitis (EAE)1, arthritis2,4, lupus5, graft-versus-host disease (GVHD)13 and transplantation7,14. In contrast, regu-
latory B-cells in humans have not been fully characterised yet. Human transitional B-cells have been shown to 
exhibit a similar phenotype to human immature B-cells from the bone marrow15,16 and a similar phenotype and 
function to murine regulatory B-cells10. In 2010, Mauri’s group demonstrated for the first time that IL-10 pro-
duced by human CD19+CD24hiCD38hi transitional B-cells after CD40 activation was able to inhibit CD4+T-cell 
pro-inflammatory cytokine production10. Furthermore, in the same study the authors showed that B-cells from 
systemic lupus erythematous patients were found to be refractory to CD40 activation with consequentially lower 
IL-10 production10. Years later, the same group demonstrated that transitional B-cells inhibited naïve T-cell dif-
ferentiation into T helper 17 and converted CD4+CD25− T-cells into regulatory T cells (Tregs) in healthy vol-
unteers, but not in patients with rheumatoid arthritis12. In GVHD, Khoder et al. reported that IgM memory 
and transitional B-cells inhibited proliferation and pro-inflammatory cytokine production by CD4+T cells in an 
IL-10-dependent manner. However, when the authors measured the IL-10 production by B-cells from patients 
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with GVHD, they observed that B-cells from patients with chronic GVHD produced less IL-10 than healthy 
donors and patients without chronic GVHD17. In kidney transplantation, higher transitional B-cell frequencies 
have been associated with reduced rejection rates18 and renal transplant recipients who developed tolerance to 
the graft displayed an increment of IL-10+transitional B-cells19,20. On the other hand, transitional B-cells are also 
involved in the immunosuppression of patients with gastric cancer via inhibition of anti-tumor T helper 1 cells 
and promotion of pro-tumor Tregs21. However, whether IL-10 produced by B-cells regulates T-cells directly or by 
interfering with B-cell activation remains unknown. In this study, we show that IL-10 produced by transitional 
B-cells down-regulates CD86 expression in an autocrine-manner, leading to the inhibition of T-cell proliferation 
and TNF-α production.
Results and Discussion
IL-10 produced by transitional B-cells down-regulates CD86 expression in an autocrine-manner. 
Human transitional B-cells produce IL-10 and regulate T-cell responses10. To gain further insights into the mech-
anisms behind the regulatory function of IL-10 produced by transitional B-cells, memory, naïve and transitional 
B-cells were FACS-sorted (Supplementary Fig. 1) from healthy blood samples and co-cultured with autologous 
anti-CD3-activated CD4+T-cells to allow for CD40L:CD40 interaction. Up-regulation of CD40L by T-cells 
was observed at 6 h post-activation (Fig. 1A); therefore CD4+T-cells were activated for 6–8 h prior co-cultur-
ing with B-cells. The production of IL-10 by B-cells co-cultured with activated CD4+T-cells was measured after 
72 h. Transitional B-cells exhibited higher percentages of IL-10+cells compared to memory B-cells (Fig. 1B). In 
contrast, the percentages of IL-10+CD4+T-cells in all of the co-cultures were lower than 2.5% (Fig. 1B). Similar 
expression of CD40 was observed between the B-cell subsets, suggesting that the differences observed in cytokine 
Figure 1. Transitional B-cells down-regulate CD86 expression through IL-10 secretion . (A) Dot plots 
and total percentages of CD40L+CD4+T-cells at 0 and 6 h post-activation with anti-CD3 (1 μ g/ml) n = 5 
****P < 0.0001 by paired t-test. (B) Dot plots and total percentages of CD20+IL-10+B-cells and CD4+IL-10+T-
cells were measured in co-cultures between anti-CD3-activated CD4+T-cells with memory, naïve or transitional 
B-cells after 72 h by intracellular staining. Individual values display the median and the range of the sample-
population represented of 5 different experiments *P < 0.05 by Friedman test with Dunn’s multiple comparison 
test. (C) Dot plots and total percentages of CD40+CD20+B-cells (black dots) were measured in the co-cultures 
after 72 h by surface staining. (D) Dot plots and total percentages of CD86+ and (E) IL-10R+ B-cells were both 
measured in B-cell subsets co-cultured with CD4+T-cells or anti-CD3-activated CD4+T-cells after 72 h of co-
culture by surface staining. (F) Dot plots and total percentages of CD86+ B-cells were measured in B-cell subsets 
co-cultured with anti-CD3-activated CD4+T-cells in the presence of a neutralising anti-IL-10 receptor antibody 
(0.1 μ g/ml) or isotype control after 72 h of co-culture by surface staining. (G) Expression of IL-10 receptor and 
IL-10 production was measured in B-cell subsets (1 × 105/well) activated with Pokeweed-mitogen (5 μ g/ml) 
for 72 h by intracellular staining. Then, the expression of CD86 was measured in B-cell subsets (1 × 105/well) 
activated with Pokeweed-mitogen (5 μ g/ml) for 72 h in the presence of three concentration of exogenous IL-10 
(10 μ g/ml, 1 μ g/ml, 0.1 μ g/ml). For D, E F and G bars in graphs represent the mean and standard error of mean 
of 4 different experiments ***P < 0.001, **P < 0.01 and *P < 0.05 by Two-way Repeated Measures Two-way 
ANOVA followed by Sidak’s multiple comparison test.
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production were not due to different susceptibility to CD40 ligation (Fig. 1C). Looking then at the other surface 
markers expressed by the B-cell subsets following the co-culture with CD4+Tcells, we observed that transitional 
B-cells expressed the lowest level of CD86 molecules (Fig. 1D) and the highest of IL-10 receptor (IL-10R) (Fig. 1E) 
compared to other B-cell subsets. Thus, we hypothesised that IL-10 secretion by transitional B-cells regulates the 
level of CD86 expression in an autocrine-manner, as previously observed in murine B-cells during an infection 
with Brugia pahangi22. To test this hypothesis, neutralising IL-10R antibody was added to the co-cultures and 
the expression of CD86 was evaluated. Blocking IL-10R significantly increased CD86 expression on transitional 
B-cells (Fig. 1F), suggesting that IL-10 was indeed down-regulating CD86 expression. To confirm the direct effect 
of IL-10 on CD86 expression, isolated B-cell subsets were activated with Pokeweed-mitogen (PWM), a mitogen 
that does not induce IL-10 secretion, in the presence of different concentrations of recombinant IL-10. After 
activation, we observed that PWM induced up-regulation of IL-10R, but not IL-10 production, in transitional 
B-cells (Fig. 1G). We confirmed that CD86 expression decreased in an IL-10-concentration-dependent manner 
only in transitional B-cells (Fig. 1G and Supplementary Fig. 2). The effect of exogenous IL-10 on the expression 
of CD86 was previously demonstrated in monocytes23 and dendritic cells (DCs)24. Moreover, the autocrine effect 
of IL-10 on CD86 down-regulation was reported in human DCs following LPS stimulation25. Furthermore, it was 
shown that on DCs:T-cell co-cultures, the IL-10-mediated down-regulation of CD86 expression inhibited T-cell 
proliferation26 and the consequence of low co-stimulation can lead to T-cell anergy and the inhibition of cytokine 
production by CD4+T-cells27. Similar to T-cell:DCs co-cultures, our results show that IL-10 produced by transi-
tional B-cells down-regulates CD86 expression in an autocrine-fashion. Thus, we decided to investigate whether 
this down-regulation has an effect on T-cell responses.
The down-regulation of CD86 molecules on transitional B-cells contributes to the inhibition of 
T-cell proliferation. Having shown that IL-10 down-regulated CD86 expression specifically in transitional 
B-cells, and knowing that the engagement of CD86 with CD28 molecules is crucial for the induction of T-cell pro-
liferation28, we then investigated the effect of neutralising IL-10 on T-cell responses. We observed that only when 
T-cells were cultured with transitional B-cells, T-cell proliferation and TNF-α production significantly increased 
in the presence of an anti-IL-10R antibody (Fig. 2A). A small increment in cell proliferation was observed in total 
CD4+T-cells when anti-IL-10R was added, however this effect disappeared when sorted effector naïve and mem-
ory CD4+T-cells were used in the co-cultures, in the complete absence of CD4+CD25hi T-cells (Supplementary 
Fig. 3). This may be explained by the fact that non-sorted CD4+T-cells exhibit 10% cell contamination and/or 
the presence of regulatory T-cells. Altogether these results further support the role of IL-10 in down-regulating 
CD86 expression leading to the inhibition of T-cell proliferation. However, we could not exclude a direct effect 
of IL-10 produced by B-cells on T-cells. To test this possibility, CD4+T-cells were activated with anti-CD3/CD28 
in the presence of different concentrations of exogenous IL-10. Although inhibition of TNF-α production in 
the presence of high concentrations of exogenous IL-10 was observed, T-cell proliferation and IL-2 production 
remained unchanged (Fig. 2B). This suggests that IL-10 produced by transitional B-cells inhibited T-cell prolif-
eration by indirectly down-regulating the antigen-presenting function of B-cells. This was further confirmed 
when the concentration of IL-10 was measured during the co-culturing of T-cells with transitional B-cells (lower 
than 0.1 ng/ml), suggesting that TNF-α inhibition was caused mainly by the low stimulatory capacity of B-cells. 
A direct effect of IL-10 on human CD4+T-cell proliferation was found to be the result of specific inhibition 
of IL-2 production29, however this mechanism cannot be applied to our system as exogenous IL-2 was added 
to all our co-cultures. Finally, to further confirm the role played by CD86 in the proliferation of CD4+T-cells, 
CD86-expressing CHO-cells were added to the co-cultures. We observed that T-cell proliferation was restored 
when CD86-expressing CHO-cells were added to the T-cell co-culture with transitional B-cells (Fig. 2C). Of note, 
although it has been reported that the inhibition of TNF-α production by CD4+T-cells, induced by transitional 
B-cells, was reverted in the presence of CD80- and CD86-neutralising antibodies10, we demonstrated that the 
level of CD86 expression on transitional B-cells correlates with the amount of TNF-α produced by CD4+T-cells. 
In the study of Blair et al., the authors argued that the regulatory mechanism of transitional B-cells could be 
similar to the one proposed by Zheng et al., where CD80 expressed on DCs acts preferentially as a ligand for 
CTLA-4 and mediates Treg cell suppression30. However, the work of Zheng et al., described an opposite effect 
of CD80 and CD86 on Tregs in terms of inhibition, therefore, the similar effect using neutralising antibodies to 
CD80 and CD86 observed by Blair et al., is intriguing. In our system, we observed a very low expression and no 
up-regulation of CD80 after CD40 activation in the transitional B-cell population (Supplementary Fig. 4) and 
neutralisation of CD86 significantly inhibited T-cell proliferation independently of the B-cell subset used in the 
co-culture (data not shown). Therefore, the differences between our results and the data presented in the previous 
studies could be due to the level of expression of CD80 on B-cells.
Higher IL-10 production by B-cells correlates with lower CD86 expression in tolerant kidney 
transplant recipients. Our results suggest that the low levels of CD86 expression might contribute to the 
regulatory function of transitional B-cells. Thus, we studied the expression of CD86 on B-cells from a cohort of 
kidney transplant recipients, either tolerant to the kidney grafts or undergoing chronic rejection (Table 1). We 
have previously shown that transitional B-cells from tolerant individuals expressed higher percentages of IL-10 
relative to stable patients19. In addition, a report from Silva et al., showed that STAT-3 phosphorylation was higher 
in regulatory B-cells from tolerant patients compared to patients with chronic rejection after CD40 activation, 
indicating that the IL-10 signalling pathway was activated in these individuals20. Here we have extended these 
observations showing that B-cells from tolerant patients, as well as the B-cells from healthy controls, both cohorts 
free from the effect of immunosuppression, expressed lower levels of CD86 molecules and higher levels of IL-10 
after CD40 ligation compared to patients with chronic rejection (Fig. 3). Altogether, our results underscore a puta-
tive new mechanism by which human transitional B-cells could regulate T-cell responses by down-modulating 
www.nature.com/scientificreports/
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CD86 expression induced by an autocrine effect of IL-10 in kidney tolerant patients. Hence, our results stress the 
importance of understanding the role of transitional B-cells in the regulation of T-cell activation. These findings 
may have relevance in kidney transplantation where the presence of transitional B-cells has been correlated with 
better kidney function post-transplant31, reduced rejection rates18 and tolerance19,32. The importance of preserv-
ing or promoting IL-10 production by a subset of B-cells may inform new therapies in renal transplant patients.
Materials and Methods
Culture conditions. RosetteSepTM Human enrichment cocktails (STEM CELL, Cambridge, UK) were used 
to obtain purified CD4+T-cells and CD20+B-cells from leukocytes retained filtering cones from healthy vol-
unteers blood donations (NHSBT Tooting blood bank, UK). CD4+T-cells were stained with Cell-Trace-Violet 
(1μ M, Life Technologies Ltd, Paisley, UK) and activated with anti-CD3 (1 μ g/ml, Sigma-Aldrich, Dorset, UK). 
CD4+T-cells were activated for 6–8 h before the addition of the B-cells. 1 × 105 CD4+T-cells were cultured with 
sorted memory, naïve or transitional B-cells (1:1 ratio) in 96 well-plates for 72 h in the presence of IL-2 (25 U/ml; 
Figure 2. IL-10 production by transitional B-cells regulates T-cell responses indirectly via down-
regulation of CD86. (A) Dot plots and total percentages of T-cell proliferation and TNF-α production of 
anti-CD3 activated CD4+T-cells co-cultured with B-cell subsets were measured in the presence of a neutralising 
anti-IL-10 receptor antibody (0.1 μ g/ml) or isotype control after 72 h. Bars in graphs represent the mean and 
standard error of 4 different experiments ***P < 0.001 and *P < 0.05 by Repeated Measures Two-way ANOVA 
test with Sidak’s multiple comparison test. (B) CD4+T-cell proliferation, TNF-α levels, IL-2 levels and IL-10 
levels in culture were measured in isolated CD4+T-cells (1 × 105) activated with anti-CD3/CD28 in the presence 
of different concentrations of exogenous IL-10 by surface staining and CBA. Bars in graphs represent the 
mean and standard error of 3 different experiments **P < 0.01 by Kruskal-Wallis test with Dunn’s multiple 
comparison test. (C) Histograms and total percentages of T-cell proliferation of 1 × 105 anti-CD3 activated 
CD4+T-cells co-cultured with 1 × 105 B-cell subsets was measured in the presence of CD86-expressing CHO-
cells and control CHO-cells (5 × 103) after 72 h. Bars in graphs represent the mean and standard error of mean 
of 3 different experiments *P < 0.05 by Repeated Measures Two-way ANOVA followed by Sidak’s multiple 
comparison test.
www.nature.com/scientificreports/
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R&D, Abingdon, UK), anti-IL-10R (0.1 μ g/ml; R&D Abingdon, UK) or isotype control. Cells were cultured 
in RPMI-1640 (Sigma-Aldrich, Dorset, UK) supplemented with L-Glutamine (2 mM), penicillin/streptomy-
cin (100 U/mL) and 10% of Foetal Bovine Serum (all Life Technologies Ltd, Paisley, UK). For some experi-
ments, Chinese hamster ovary (CHO)-cells and CD86-expressing CHO-cells, kindly provided by Prof. David 
Sansom33,34, were added to the T-B cell co-cultures. CHO-cells and CD86-expressing CHO-cells were fixed with 
Glutaraldehyde (0.025%; Sigma-Aldrich, Dorset, UK) at room temperature for 2–3 min. Then, CHO-cells and 
CD86-expressing CHO-cells were added to co-cultures (1:20 ratio) after CD86 expression was confirmed by 
surface staining. Exogenous IL-10 (eBioscience, Hatfield, UK) was added to sorted-B-cell subsets activated with 
Pokeweed-mitogen (5 ug/ml, Life Technologies Ltd, Paisley, UK) for 72 h and to anti-CD3/CD28 (1 μ g/ml)-ac-
tivated CD4+T-cells (1 × 105). Cells were stained with anti-CD20-AlexaFluor780, anti-CD3-PerCP-Cy5.5, anti-
CD40-APC, anti-CD86-PE/FITC, anti-CD40L-PE, anti-CD4-PacBlue, anti-IL10R-PE (all eBioscience, Hatfield, 
UK) and the corresponding isotype/FMO (Fluorescent minus one) controls for 30 min/4 °C. Cells were activated 
with PMA (50ng/mL), ionomicyn (1 ug/mL), GolgiStop and Brefeldin A (all BD Biosciences, Oxford, UK) for 5 h. 
Cells were fixed and permeabilised with Foxp3/Transcription Factor Staining Buffer Set (eBioscience, Hatfield, 
UK) and stained with IL-10-PE (BD Biosciences, Oxford, UK), TNF-α -PECy7 (eBioscience, Hatfield, UK), and 
the corresponding isotype/FMO controls for 30 min at 4 °C. Cells were acquired on an LSRFortessa (BD). Data 
was analysed using FlowJo (Tree Star Inc., Ashland, OR, USA). BD Cytometric Bead Array (CBA) (Th1/Th2/
Patient Data
Healthy 
Control Tolerant
Chronic 
Rejection
Age in years [mean (range)] 50.1 (23–72) 49.9 (22–77) 47.0 (29–72)
Number of patients 10 10 10
Sex
 Male 8 7 8
 Female 2 3 2
Recipient age at Transpl [mean (range)] — 29.2 (11–52) 39.1 (17–70)
Donor (Living/Deceased) — (5/5) (5/5)
Time post transplantation in years [mean 
(range)] — 20.7 (10–34) 7.9 (2–26)
HLA mismatches per group
 Number of patients with no mismatches — 2 0
 Number of patients with HLA (A or B) 
mismatches — 1 0
 Number of patients with HLA (A and B) 
mismatches — 1 4
 Number of patients with HLA (A + DR) 
mismatches — 0 1
 Number of patients with HLA (B + DR) 
mismatches — 0 1
 Number of patients with HLA (A, B, DR) 
mismatches — 5 4
 Missing data — 1 0
Immunosuppressive Regime
 CNI + MMF — 0 1
 CNI + Aza — 0 1
 CNI + Steroids 0 1
 CNI + MMF + Steroids — 0 5
 CNI + Aza + Steroids — 0 2
Donor-specific antibodies
 No DSA — 9 4
 DSA Class I — 1 2
 DSA Class II — 0 2
 DSA Class I and II — 0 2
Renal Function Parameters
 Creatinine (mmols/L) [mean] — 115.4 252.2
 eGFR (mL/min/1.73m2) [mean] — 65.3 27.1
Cell Count
 Lymphocytes count x 109 2.20 2.29 1.25
 B-cell count x109 0.32 0.42 0.13
Table 1.  Clinical data of kidney transplant recipients and healthy volunteers. CNI: Calcineurin inhibitors. 
MMF: mycophenolate mofetil. AZA: azathioprine. DSA: donor-specific antibodies. eGFR: estimated glomerular 
filtration rate.
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Th17 Kit;BD Biosciences, Oxford, UK) and ELISA eBioscience, Hatfield, UK) were performed to measure levels 
of cytokines in culture.
Patients. Procurement of patient samples was facilitated by the Genetic Analysis & Monitoring of Biomarker 
of Immunological Tolerance (GAMBIT) study, approved by the Institute of Child Health/Great Ormond Street 
Hospital Research Ethics Committee 09/H0713/12. All experiments were performed in accordance with the 
approved guidelines and regulations. Samples were processed and analysed in a blinded fashion after informed 
consent was obtained from all subjects. Of all the patients included in the GAMBIT study, the following ones 
have been used in this project: Tolerant (n = 10): Functionally stable kidney transplant recipients despite having 
stopped all their immunosuppression for longer than one year. Patients with chronic rejection (n = 10): Kidney 
transplant recipients with graft dysfunction, despite adequate immunosuppression, and a recent biopsy showing 
signs of immunologically driven chronic rejection in accordance with the BANFF Criteria35. Healthy control 
(n = 10): Healthy volunteers age and gender matched to renal transplant patients.
The characteristics of the individuals from each group are described in Table 1 and detailed patient data is 
described in Supplementary Table 1.
Patient samples processing. PBMCs were isolated from peripheral blood by Ficoll-Hypaque (PAA, 
Pasching, Austria) density gradient centrifugation and stored in liquid nitrogen until use.
Functional assay for patient samples. PBMCs samples were thawed from liquid nitrogen on the 
same day as the staining and 3 × 106 PBMCs were stained with Live/Dead (Life Technologies Ltd, Paisley, 
UK), anti-CD20-AlexaFluor780 and CD86-PE (all eBioscience, Hatfield, UK) for 30 min/4 °C. 1 × 106 PBMCs 
from patient samples were rested overnight and the next day cells were cultured with 0.5 × 105 plate bound 
human-CD40L-transfected and non-transfected mouse L fibroblast cells (X-ray irradiated for 30 min 9,045 cGy) 
for 72 h. Intracellular IL-10-PE (BD) was measured in CD20+B-cells after CD40L activation.
Statistical analysis. All columns in graphs represent the mean and standard error of mean of 3 to 5 inde-
pendent experiments. Individual values display the median and the range of the sample-population represented. 
For the analysis of the expression of CD40L at 0 and 6 h post-activation (paired), the P value was analysed from 
a paired t-test test. For the analysis of the IL-10 production between T-B-cell subsets (repeated measured/
non-parametric), the P values were analysed using Friedman test with Dunn’s multiple comparison. For the anal-
ysis of the IL-10 production and CD86 expression between patient’s groups (no pairing/non-parametric), the P 
values were analysed using Kruskal-Wallis test with Dunn’s multiple comparison. For the analysis of the IL-10R, 
CD86 and TNF-α expression and proliferation between T-B-cell subsets and activating-conditions/anti-IL-10R/
CHO-cells (repeated measured/parametric/two-way), the P values were analysed using Repeated Measures 
Two-way ANOVA test with Sidak’s multiple comparison. The statistical analysis and the figures were prepared 
using Prism (GraphPad Software, La Jolla, CA, USA). P value < 0.05 was considered significant.
Figure 3. B-cell from tolerant kidney transplant recipient maintained low expression of CD86 and high 
production of IL-10 compared to patients with chronic rejection. Representative dot plots of CD86 and IL-10 
expression by B-cells from Healthy controls (HC), Tolerant recipients (Tol) and patients with chronic rejection 
(CR). Total percentages of CD86 expression were measured in 1 × 106 PBMCs from HC, Tol and CR by surface 
staining. IL-10 production was measured in B-cells form patient samples (1.0 × 106 PBMCs) by intracellular 
staining after 72 h of stimulation with 5 × 104 non-transfected or CD40L-transfected L cells (plate-bound and 
irradiated). Bars in graphs represent the mean and standard error **P < 0.01 and *P < 0.05 by Kruskal-Wallis 
test with Dunn’s multiple comparison test.
www.nature.com/scientificreports/
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